Discovery research service from Amphora
Amphora's Discovery business unit, a division of global biotech firm Amphora, has launched a contract research service that aims to enable pharmaceutical and biotech companies to improve the quality and reduce the timelines for drug discovery.
Amphora's Discovery business unit, a division of global biotech firm Amphora, has launched a contract research service that aims to enable pharmaceutical and biotech companies to improve the quality and reduce the timelines for drug discovery.
The new service will feature Amphora Discovery's chemogenomic, systems biology, and high precision microfluidics technologies that improve the efficiency of lead generation and optimisation through a process that shortens traditional timelines.
'Since our inception we have performed over 100 high-throughput screens and have generated over 35 million data points,' said Bill Janzen, founder and chief technology officer at Amphora Discovery.
'With our efficient process and microfluidic screening approach, we have found that our screening and profiling costs are a fraction of those seen with many traditional assay formats, and our PrecisionProtocol products provide a way for customers to access our validated ready-to-screen protocols to increase their in-house screening and profiling efficiencies,' Janzen added.
PrecisionProtocol assays are developed to provide comparable biochemical and kinetic conditions across assays, enabling the determination of true selectivity early in the discovery process, Amphora Discovery says.
Primary screening results can then be used for direct Structure Activity Relationship (SAR) mining, avoiding lengthy retest times and allowing the selection and prioritisation of the best chemical series for further development.